ESPR
Esperion Therapeutics Inc
3.20$
+0.0%
vs. previous close
Closing price · As of: Jul 15, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +106.2% | -17.0% | +13.3% | -48.4% | +49.5% | +64.7% | +8.0% | -35.0% | -17.0% | +67.1% | +35.5% | |
| – | +100.8% | -0.4% | -4.5% | -30.1% | +48.4% | +63.4% | -4.9% | -25.0% | -18.5% | +68.1% | +36.9% | |
| – | -9.1% | -50.7% | -9.7% | +7.3% | +349.3% | +83.6% | -31.5% | -40.3% | -34.1% | +76.0% | +16.0% | |
| – | -9.1% | -50.7% | -9.7% | +7.3% | +443.0% | +51.9% | -15.0% | -35.7% | -50.7% | +76.0% | +16.0% | |
| – | – | – | – | – | – | – | +85.1% | +47.1% | +43.8% | +65.3% | +74.9% | |
| – | – | – | – | – | – | – | +113.2% | +2.3% | +86.4% | +44.0% | +11.3% | |
| – | +3.5% | -16.5% | -35.5% | +19.5% | +120.2% | +11.4% | -48.0% | -75.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -15.1% | +99.8% | +99.5% | +94.1% | +202.3% | +131.1% | +28.7% | -1.2% | +15.6% | +10.9% | +4.8% | |
| – | +2.4% | +177.1% | +112.6% | +94.1% | +2.7% | +42.4% | -22.0% | +25.8% | +69.2% | +57.6% | +22.2% | |
| – | +151.4% | +6.5% | -38.9% | – | – | +469.8% | +444.2% | +81.3% | +42.5% | +188.3% | -12.5% | |
| – | -65.3% | +549.9% | +343.4% | +120.3% | -35.7% | +80.1% | -66.2% | +31.2% | +37.7% | +62.8% | +26.0% | |
| – | -37.5% | -62.0% | -100.0% | – | – | +40.9% | +44.0% | +0.6% | +0.7% | -9.1% | +4.9% | |
| – | +115.1% | -20.4% | +7.0% | -344.4% | – | -581.9% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +34.5% | +2.4% | +6.2% | +11.8% | +1.3% | +1.4% | +5.2% | +129.8% | +55.3% | +81.5% | +11.0% |
Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.